objective B-abstraction
we O
investigated O
the O
expression B-abstraction
and O
potential O
roles O
of O
interleukin O
il O
2 O
, O
il O
4 O
, O
il O
6 O
, O
il O
10 O
, O
il O
17a O
, O
il O
37 O
, O
interferon O
ifn O
gamma O
, O
and O
tumor O
necrosis O
factor B-abstraction
tnf O
in O
patients O
with O
adenomyosis O
. O

materials O
and O
methods O
this O
prospective O
study B-physical_entity
examined O
16 O
women O
with O
histologically O
proven O
adenomyosis O
and O
52 O
women O
without O
adenomyosis O
, O
all O
of O
whom O
were O
undergoing O
a O
hysterectomy B-abstraction
for O
non O
endometrial O
pathology B-abstraction
at O
the O
department B-physical_entity
of O
gynaecology B-abstraction
, O
the O
first B-abstraction
hospital B-physical_entity
of O
jilin O
university B-physical_entity
, O
changchun O
, O
china B-physical_entity
, O
from O
december O
2011 O
to O
september O
2012 O
. O

serum O
samples O
were O
collected O
from O
the O
patients O
, O
and O
the O
concentrations O
of O
serum O
il O
2 O
, O
il O
4 O
, O
il O
6 O
, O
il O
10 O
, O
il O
17a O
, O
il O
37 O
, O
ifn O
gamma O
, O
and O
tnf O
were O
measured O
by O
enzyme O
linked O
immunosorbent O
assay B-abstraction
elisa O
. O

we O
then O
calculated O
specificity B-abstraction
and O
sensitivity B-abstraction
of O
cytokines O
, O
taking B-abstraction
cancer O
antigen O
ca O
125 O
as O
a O
reference B-abstraction
, O
distinguishing O
cases O
from O
controls O
by O
receiver B-physical_entity
operating O
characteristic B-abstraction
roc B-abstraction
curve B-abstraction
. O

the O
correlation B-abstraction
between O
individual B-physical_entity
cytokines O
and O
ca O
125 O
was O
also O
analysed O
. O

results O
il O
37 O
was O
detectable O
in O
69 O
. O

2 O
and O
the O
other O
cytokines O
in O
30 O
. O

8 O
of O
sera O
samples O
from O
the O
52 O
controls O
. O

all O
the O
eight O
cytokines O
were O
detectable O
in O
the O
sera O
samples O
from O
16 O
patients O
with O
adenomyosis O
. O

significantly O
higher O
levels O
of O
serum O
il O
37 O
and O
il O
10 O
and O
significantly O
lower B-physical_entity
levels O
of O
serum O
il O
17a O
and O
tnf O
were O
detected O
in O
adenomyosis O
patients O
when O
compared O
with O
controls O
p O
0 O
. O

05 O
. O

conclusions O
serum O
levels O
of O
il O
10 O
, O
il O
17a O
, O
il O
37 O
, O
and O
tnf O
varied O
significantly O
between O
cases O
and O
controls O
, O
and O
could O
be O
involved O
in O
the O
pathogenesis B-physical_entity
of O
adenomyosis O
. O


objectives O
inflammatory O
response B-physical_entity
and O
cytokine O
activation B-abstraction
are O
markedly O
stimulated O
in O
skeletal O
muscle B-abstraction
during O
various O
conditions O
. O

interleukin O
6 O
il O
6 O
, O
a O
pro B-physical_entity
inflammatory O
cytokine O
, O
has O
pleiotropic O
effects O
on O
skeletal O
muscle B-abstraction
. O

adenosine O
, O
released O
by O
all O
cell B-physical_entity
types O
, O
binds O
to O
a O
class B-abstraction
of O
g O
protein O
coupled O
receptors O
to O
induce O
various O
skeletal O
muscle B-physical_entity
effects O
. O

the O
aim B-abstraction
of O
this O
work B-physical_entity
was O
to O
investigate O
whether O
activation B-physical_entity
of O
adenosine O
receptors O
, O
particularly O
adenosine O
a2b O
receptors O
, O
could O
stimulate O
il O
6 O
gene O
expression B-abstraction
in O
rat B-physical_entity
l6 O
skeletal O
muscle B-physical_entity
cells O
. O

materials O
and O
methods O
the O
rat B-physical_entity
l6 O
skeletal O
muscle B-physical_entity
cells O
were O
cultured O
in O
25 O
cm2 O
flasks O
. O

these O
differentiated O
cells O
were O
treated O
and O
then O
quantitative O
reverse B-abstraction
transcription B-abstraction
polymerase O
chain B-physical_entity
reaction I-physical_entity
probe B-abstraction
based O
was O
used O
to O
analyze O
il O
6 O
gene O
expression B-physical_entity
level B-physical_entity
among O
different O
treatment B-abstraction
conditions O
. O

results O
adenosine O
5' O
n O
ethyluronamide O
neca O
, O
a O
stable B-physical_entity
adenosine O
analogue B-abstraction
, O
concentration B-abstraction
and O
time B-abstraction
dependently O
stimulates O
il O
6 O
gene O
expression B-abstraction
in O
skeletal O
muscle B-abstraction
cells O
. O

the O
effect B-abstraction
of O
neca O
is O
inhibited O
by O
a O
selective O
adenosine O
a2b O
receptor O
antagonist B-physical_entity
, O
psb O
603 O
. O

by O
using B-abstraction
cyclic O
adenosine O
monophosphate O
camp B-abstraction
arising O
reagent O
forskolin O
, O
camp B-abstraction
is O
found O
to O
be O
involved O
in O
the O
up O
regulation B-physical_entity
of O
il O
6 O
induction B-abstraction
. O

conclusion B-abstraction
here B-physical_entity
, O
a O
novel B-physical_entity
relationship O
between O
adenosine O
and O
il O
6 O
up O
regulation B-physical_entity
has O
been O
demonstrated O
for O
the O
first B-physical_entity
time B-abstraction
; O
il O
6 O
up O
regulation B-physical_entity
induced O
by O
neca O
is O
mediated O
by O
adenosine O
a2b O
receptor O
activation B-abstraction
in O
skeletal O
muscle B-abstraction
and O
is O
dependent B-physical_entity
on O
mainly O
a O
camp B-physical_entity
pathway B-physical_entity
. O

adenosine O
a2b O
receptors O
are O
, O
thus O
, O
potentially O
important O
pharmacological O
targets O
in O
treating O
inflammation B-abstraction
and O
related O
diseases O
in O
skeletal O
muscle B-abstraction
tissues O
. O


adenosine O
triphosphate O
binding B-abstraction
cassette B-physical_entity
proteins O
constitute O
a O
large B-abstraction
family B-physical_entity
of O
active B-physical_entity
transporters O
through O
extracellular O
and O
intracellular O
membranes O
. O

increased O
drug O
efflux B-physical_entity
based O
on O
adenosine O
triphosphate O
binding B-physical_entity
cassette B-physical_entity
protein O
activity B-physical_entity
is O
related O
to O
the O
development B-abstraction
of O
cancer B-O
cell I-O
chemoresistance O
. O

several O
articles O
have B-physical_entity
focused O
on O
adenosine O
triphosphate O
binding B-abstraction
cassette B-physical_entity
gene O
expression B-abstraction
profiles O
signatures O
, O
based O
on O
the O
expression B-abstraction
of O
all O
49 O
human B-physical_entity
adenosine O
triphosphate O
binding B-physical_entity
cassette B-physical_entity
genes O
, O
in O
individual B-physical_entity
tumor O
types O
and O
reported O
connections O
to O
established O
clinicopathological O
features O
. O

the O
aim B-abstraction
of O
this O
study B-abstraction
was O
to O
test B-abstraction
our O
theory B-abstraction
about O
the O
existence B-physical_entity
of O
adenosine O
triphosphate O
binding B-physical_entity
cassette B-physical_entity
gene O
expression B-physical_entity
profiles O
common B-physical_entity
to O
multiple B-abstraction
types O
of O
tumors O
, O
which O
may B-physical_entity
modify O
tumor O
progression B-abstraction
and O
provide O
clinically O
relevant O
information B-abstraction
. O

such O
general B-physical_entity
adenosine O
triphosphate O
binding B-physical_entity
cassette B-physical_entity
profiles O
could O
constitute O
a O
new O
attribute B-abstraction
of O
carcinogenesis O
. O

our O
combined O
cohort O
consisted O
of O
tissues O
from O
151 O
cancer O
patients O
breast O
, O
colorectal O
, O
and O
pancreatic O
carcinomas O
. O

standard B-physical_entity
protocols O
for O
rna O
isolation B-physical_entity
and O
quantitative O
real B-O
time I-O
polymerase O
chain B-physical_entity
reaction I-physical_entity
were O
followed O
. O

gene O
expression B-abstraction
data O
from O
individual B-physical_entity
tumor O
types O
as O
well B-physical_entity
as O
a O
merged O
tumor O
dataset O
were O
analyzed O
by O
bioinformatics O
tools O
. O

several O
general B-physical_entity
adenosine O
triphosphate O
binding B-abstraction
cassette B-physical_entity
profiles O
, O
with O
differences O
in O
gene O
functions O
, O
were O
established O
and O
shown O
to O
have B-physical_entity
significant O
relations O
to O
clinicopathological O
features O
such O
as O
tumor O
size B-abstraction
, O
histological O
grade B-physical_entity
, O
or O
clinical O
stage B-abstraction
. O

genes O
abcc7 O
, O
a3 O
, O
a8 O
, O
a12 O
, O
and O
c8 O
prevailed O
among O
the O
most O
upregulated O
or O
downregulated O
ones O
. O

in O
conclusion B-abstraction
, O
the O
results O
supported O
our O
theory B-abstraction
about O
general B-physical_entity
adenosine O
triphosphate O
binding B-physical_entity
cassette B-physical_entity
gene O
expression B-physical_entity
profiles O
and O
their O
importance B-abstraction
for O
cancer O
on O
clinical O
as O
well B-physical_entity
as O
research B-abstraction
levels O
. O

the O
presence B-physical_entity
of O
abcc7 O
official B-physical_entity
symbol B-abstraction
cftr O
among O
the O
genes O
with O
key B-abstraction
roles O
in O
the O
profiles O
supports O
the O
emerging O
evidence B-abstraction
about O
its O
crucial O
role B-abstraction
in O
various O
cancers O
. O


background B-abstraction
to O
perform O
a O
molecular O
epidemiological O
analysis B-abstraction
of O
viral O
conjunctivitis B-abstraction
among O
excess B-abstraction
conjunctivitis B-abstraction
cases O
recorded O
at O
the O
university B-physical_entity
hospital B-physical_entity
of O
patras O
, O
greece O
, O
for O
the O
period B-physical_entity
march B-physical_entity
to O
june O
2012 O
. O

methods O
a O
structured O
questionnaire O
containing O
demographic B-abstraction
and O
clinical O
data O
was O
developed O
in O
order B-abstraction
to O
collect B-abstraction
retrospective O
data O
on O
the O
cases O
. O

eye B-physical_entity
swab B-physical_entity
specimens O
were O
collected O
and O
molecular O
detection B-physical_entity
of O
adenoviruses O
was O
performed O
by O
nested O
pcr O
. O

positive B-physical_entity
results O
were O
confirmed O
by O
sequencing O
. O

to O
determine O
the O
relatedness O
between O
the O
isolated O
sequences O
, O
a O
phylogenetic O
analysis B-abstraction
was O
conducted O
. O

results O
the O
epidemiological O
analysis B-abstraction
including O
retrospective O
data O
included O
231 O
conjunctivitis B-abstraction
cases O
47 O
. O

1 O
male B-physical_entity
, O
and O
52 O
. O

8 O
female B-physical_entity
. O

based O
on O
clinical O
features O
205 O
of O
the O
cases O
were O
diagnosed O
of O
viral O
origin B-physical_entity
46 O
. O

3 O
male B-physical_entity
and O
53 O
. O

7 O
female B-physical_entity
, O
4 O
of O
bacterial O
origin B-abstraction
50 O
male B-physical_entity
and O
50 O
female B-physical_entity
while B-abstraction
22 O
were O
undefined O
conjunctivitis B-abstraction
. O

the O
outbreak B-abstraction
excess B-abstraction
cases O
included O
156 O
cases O
affected O
all O
age B-abstraction
groups O
regardless O
gender B-abstraction
predilection B-abstraction
. O

for O
the O
positive B-physical_entity
samples O
indicated O
that O
29 O
samples O
72 O
. O

5 O
were O
adv17 O
, O
and O
5 O
12 O
. O

5 O
as O
adv54 O
. O

conclusions O
molecular O
analysis B-abstraction
could O
define O
the O
cause B-abstraction
of O
viral O
conjunctivitis B-abstraction
, O
while B-abstraction
epidemiological O
data O
contributed O
to O
the O
assessment B-abstraction
of O
the O
risk B-abstraction
factors O
and O
underlined O
possible B-physical_entity
preventive B-physical_entity
measures O
. O

this O
study B-physical_entity
is O
one B-abstraction
of O
the O
very O
few O
on O
viral O
conjunctivitis B-abstraction
in O
greece O
. O

this O
outbreak B-abstraction
underscores O
the O
need B-abstraction
for O
a O
national B-physical_entity
surveillance B-abstraction
system I-abstraction
for O
acute O
infectious O
conjunctivitis B-abstraction
outbreaks O
. O

the O
epidemiological O
as O
well B-physical_entity
as O
molecular O
investigation B-abstraction
on O
hadv O
ocular B-physical_entity
infections O
is O
rather O
absent O
in O
greece O
, O
which O
has O
no B-abstraction
surveillance B-abstraction
system I-abstraction
for O
viral O
conjunctivitis B-abstraction
. O


the O
dopamine O
receptor O
d4 O
and O
the O
dopamine O
transporter B-physical_entity
have B-physical_entity
been O
investigated O
for O
their O
role B-abstraction
in O
attention B-abstraction
deficit B-abstraction
hyperactivity O
disorder O
adhd O
in O
children O
. O

reports O
of O
their O
genetic O
association B-abstraction
with O
adhd O
have B-physical_entity
shown O
mixed O
results O
. O

the O
aim B-physical_entity
of O
the O
study B-abstraction
was O
to O
evaluate O
the O
association B-physical_entity
of O
variable B-physical_entity
number B-abstraction
tandem B-physical_entity
repeats O
vntrs O
of O
the O
drd4 O
and O
dat1 O
genes O
with O
adhd O
in O
children O
. O

a O
pilot B-abstraction
1 O
1 O
case B-abstraction
control B-abstraction
study B-physical_entity
, O
with O
44 O
clinically O
confirmed O
adhd O
cases O
and O
44 O
age B-abstraction
gender B-abstraction
matched O
healthy O
controls O
, O
was O
conducted O
at O
a O
tertiary O
care B-abstraction
centre B-physical_entity
in O
mumbai O
. O

variable B-abstraction
number B-physical_entity
tandem B-physical_entity
repeats O
of O
drd4 O
exon O
3 O
, O
dat1 O
intron O
8 O
and O
3'utr O
were O
genotyped O
by O
pcr O
age B-abstraction
. O

several O
allele O
repeats O
of O
the O
genes O
were O
observed O
in O
the O
screened O
subjects O
. O

statistical O
significance B-abstraction
was O
observed O
for O
the O
10r O
10r O
genotype B-abstraction
of O
the O
dat1 O
3'utr O
vntr O
between O
cases O
and O
controls O
. O


objective B-abstraction
endothelial O
activation B-abstraction
is O
implicated O
in O
atherogenesis O
and O
diabetes O
. O

the O
role B-abstraction
of O
peroxisome O
proliferator O
activated O
receptor O
delta B-physical_entity
ppar O
delta B-physical_entity
in O
endothelial O
activation B-abstraction
remains B-physical_entity
poorly O
understood O
. O

in O
this O
study B-physical_entity
, O
we O
investigated O
the O
anti B-physical_entity
inflammatory O
effect B-abstraction
of O
ppar O
delta B-physical_entity
and O
the O
mechanism B-physical_entity
involved O
. O

methods O
and O
results O
in O
human B-physical_entity
umbilical O
vein B-physical_entity
endothelial O
cells O
huvecs O
, O
the O
synthetic O
ppar O
delta B-physical_entity
ligands O
gw0742 O
and O
gw501516 O
significantly O
inhibited O
tumor O
necrosis O
factor B-abstraction
tnf O
alpha B-abstraction
induced O
expression B-physical_entity
of O
vascular O
cell B-physical_entity
adhesion B-abstraction
molecule O
1 O
and O
e O
selectin O
assayed O
by O
real B-O
time I-O
rt O
pcr O
and O
northern O
blotting O
, O
as O
well B-physical_entity
as O
the O
ensuing O
endothelial O
leukocyte B-physical_entity
adhesion B-abstraction
. O

activation B-physical_entity
of O
ppar O
delta B-physical_entity
upregulated O
the O
expression B-physical_entity
of O
antioxidant O
genes O
superoxide B-physical_entity
dismutase O
1 O
, O
catalase O
, O
and O
thioredoxin O
and O
decreased O
reactive O
oxygen O
species B-abstraction
production B-abstraction
in O
ecs O
. O

chromatin O
immunoprecipitation O
assays O
showed O
that O
gw0742 O
switched O
the O
association B-physical_entity
of O
bcl O
6 O
, O
a O
transcription B-physical_entity
repressor O
, O
from O
ppar O
delta B-physical_entity
to O
the O
vascular O
cell B-physical_entity
adhesion B-abstraction
molecule O
vcam O
1 O
promoter B-physical_entity
. O

small B-abstraction
interfering O
rna O
reduced O
endogenous O
ppar O
delta B-physical_entity
expression B-physical_entity
but O
potentiated O
the O
suppressive O
effect B-abstraction
of O
gw0742 O
on O
ec O
activation B-abstraction
, O
which O
suggests O
that O
the O
nonliganded O
ppar O
delta B-physical_entity
may B-physical_entity
have B-physical_entity
an O
opposite B-physical_entity
effect B-abstraction
. O

conclusions O
we O
have B-physical_entity
demonstrated O
that O
ligand O
activation B-physical_entity
of O
ppar O
delta B-physical_entity
in O
ecs O
has O
a O
potent O
antiinflammatory O
effect B-abstraction
, O
probably O
via O
a O
binary B-physical_entity
mechanism B-abstraction
involving O
the O
induction B-abstraction
of O
antioxidative O
genes O
and O
the O
release B-abstraction
of O
nuclear O
corepressors O
. O

ppar O
delta B-physical_entity
agonists O
may B-physical_entity
have B-physical_entity
a O
potential O
for O
treating O
inflammatory O
diseases O
such O
as O
atherosclerosis O
and O
diabetes O
. O


aims O
hypothesis B-abstraction
the O
aim B-physical_entity
of O
this O
study B-physical_entity
was O
to O
investigate O
changes O
in O
insulin O
sensitivity B-abstraction
and O
expression B-physical_entity
of O
the O
gene O
encoding B-abstraction
resistin O
retn O
in O
adipocytes O
from O
long O
term B-physical_entity
nitric O
oxide O
no B-abstraction
deficient O
rats O
. O

methods O
male B-physical_entity
sprague O
dawley O
rats O
received O
n O
omega B-abstraction
nitro O
larginine O
methyl O
ester O
l O
name B-physical_entity
0 O
. O

5 O
mg O
ml O
in O
their O
drinking B-abstraction
water B-physical_entity
for O
4 O
weeks O
, O
while B-abstraction
control B-abstraction
rats O
received O
plain B-physical_entity
drinking B-abstraction
water B-physical_entity
. O

during O
the O
experimental O
period B-physical_entity
, O
changes O
in O
plasma O
glucose O
, O
insulin O
and O
c O
peptide O
levels O
were O
measured O
. O

after O
administration B-abstraction
of O
l O
name B-abstraction
for O
4 O
weeks O
, O
insulin O
sensitivity B-abstraction
was O
evaluated O
in O
vivo O
and O
in O
vitro O
. O

an O
insulin O
binding B-abstraction
assay B-abstraction
was O
also O
performed O
to O
determine O
the O
number B-physical_entity
and O
binding B-physical_entity
affinity B-abstraction
of O
insulin O
receptors O
in O
adipocytes O
. O

adipocyte O
retn O
mrna O
levels O
were O
examined O
using B-abstraction
northern O
blotting O
. O

results O
successful O
induction B-abstraction
of O
no B-abstraction
deficiency B-abstraction
was O
demonstrated O
by O
an O
increase B-abstraction
in O
systemic O
blood B-physical_entity
pressure I-physical_entity
. O

no B-abstraction
difference B-abstraction
in O
plasma O
glucose O
levels O
was O
found O
between O
the O
two O
groups O
. O

compared O
with O
the O
control B-abstraction
rats O
, O
plasma O
insulin O
and O
c O
peptide O
levels O
were O
significantly O
decreased O
in O
the O
no B-abstraction
deficient O
rats O
, O
and O
insulin O
sensitivity B-abstraction
was O
significantly O
increased O
. O

insulin O
stimulated O
glucose O
uptake B-physical_entity
and O
insulin O
binding B-physical_entity
capacity B-abstraction
, O
but O
not O
binding B-physical_entity
affinity B-abstraction
, O
were O
significantly O
increased O
in O
adipocytes O
isolated O
from O
no B-abstraction
deficient O
rats O
. O

in O
addition B-physical_entity
, O
adipocyte O
retn O
mrna O
levels O
, O
but O
not O
plasma O
resistin O
levels O
, O
were O
significantly O
decreased O
in O
no B-abstraction
deficient O
rats O
, O
and O
the O
retn O
mrna O
levels O
were O
negatively O
correlated O
with O
insulin O
sensitivity B-abstraction
. O

conclusions O
interpretation B-abstraction
insulin O
sensitivity B-abstraction
was O
increased O
in O
no B-abstraction
deficient O
rats O
and O
this O
was O
associated O
with O
insulin O
binding B-physical_entity
capacity B-abstraction
and O
downregulated O
retn O
expression B-physical_entity
. O

these O
findings O
suggest O
that O
no B-abstraction
plays O
a O
regulatory O
role B-abstraction
in O
metabolism B-physical_entity
. O

dysregulation O
of O
no B-abstraction
production B-abstraction
may B-physical_entity
result B-abstraction
in O
the O
development B-abstraction
of O
metabolic O
disorders O
. O


leptin O
is O
an O
adipocytokine O
that O
regulates O
body B-abstraction
weight I-abstraction
, O
and O
maintains O
energy B-abstraction
homeostasis O
by O
promoting O
reduced O
food B-abstraction
intake B-physical_entity
and O
increasing O
energy B-abstraction
expenditure B-abstraction
. O

leptin O
expression B-physical_entity
and O
secretion B-physical_entity
is O
regulated O
by O
various O
factors O
including O
hormones O
and O
fatty B-physical_entity
acids O
. O

butyrate O
is O
a O
short B-physical_entity
chain B-physical_entity
fatty B-physical_entity
acid O
that O
acts O
as O
source B-abstraction
of O
energy B-abstraction
in O
humans B-physical_entity
. O

we O
determined O
whether O
this O
fatty B-physical_entity
acid O
can B-physical_entity
play B-abstraction
a O
role B-abstraction
in O
leptin O
expression B-physical_entity
in O
fully O
differentiated O
human B-physical_entity
adipocytes O
. O

mature O
differentiated O
adipocytes O
were O
incubated O
with O
or O
without O
increasing O
concentrations O
of O
butyrate O
. O

rna O
was O
extracted O
and O
leptin O
mrna O
expression B-physical_entity
was O
examined O
by O
northern O
blot B-abstraction
analysis B-abstraction
. O

moreover O
, O
the O
cells O
were O
incubated O
with O
regulators O
that O
may B-physical_entity
affect O
signals O
which O
may B-physical_entity
alter O
leptin O
expression B-physical_entity
and O
analyzed O
with O
northern O
blotting O
. O

butyrate O
stimulated O
leptin O
expression B-abstraction
, O
and O
stimulated O
mitogen O
activated O
protein O
kinase O
mapk O
and O
phospho O
creb O
signaling O
in O
a O
time B-abstraction
dependent B-physical_entity
manner B-abstraction
. O

prior B-physical_entity
treatment B-abstraction
of O
the O
cells O
with O
signal B-abstraction
transduction B-physical_entity
inhibitors O
as O
pertusis O
toxin O
, O
g O
i O
protein O
antagonist B-physical_entity
, O
pd98059 O
a O
mapk O
inhibitor O
, O
and O
wortmannin O
a O
pi3k O
inhibitor O
abolished O
leptin O
mrna O
expression B-abstraction
. O

these O
results O
suggest O
that O
butyrate O
can B-physical_entity
regulate O
leptin O
expression B-abstraction
in O
humans B-physical_entity
at O
the O
transcriptional O
level B-abstraction
. O

this O
is O
accomplished O
by O
1 O
g O
i O
protein O
coupled O
receptors O
specific B-abstraction
for O
short B-abstraction
chain B-physical_entity
fatty B-physical_entity
acids O
, O
and O
2 O
mapk O
and O
phosphatidylinositol O
3 O
kinase O
p13k O
signaling O
pathways O
. O


expression B-physical_entity
of O
the O
glut4 O
glucose O
transporter B-physical_entity
type B-physical_entity
4 O
isoform O
gene O
in O
adipocytes O
is O
subject B-physical_entity
to O
hormonal O
or O
metabolic O
control B-physical_entity
. O

in O
the O
present B-abstraction
study B-physical_entity
, O
we O
have B-physical_entity
characterized O
an O
adipose O
tissue O
transcription B-physical_entity
factor B-abstraction
that O
is O
influenced O
by O
fasting B-abstraction
refeeding O
regimens O
and O
insulin O
. O

northern O
blotting O
showed O
that O
refeeding O
increased O
glut4 O
mrna O
levels O
for O
24 O
h O
in O
adipose O
tissue O
. O

consistent O
with O
an O
increased O
glut4 O
gene O
expression B-physical_entity
, O
the O
mrna O
levels O
of O
srebp O
sterol O
regulatory O
element B-abstraction
binding B-physical_entity
protein O
1c O
in O
adipose O
tissue O
were O
also O
increased O
by O
refeeding O
. O

in O
streptozotocin O
induced O
diabetic B-physical_entity
rats O
, O
insulin O
treatment B-abstraction
increased O
the O
mrna O
levels O
of O
glut4 O
in O
adipose O
tissue O
. O

serial B-physical_entity
deletion B-abstraction
, O
luciferase O
reporter B-physical_entity
assays O
and O
electrophoretic O
mobility B-abstraction
shift B-abstraction
assay B-abstraction
studies O
indicated O
that O
the O
putative O
sterol O
response B-abstraction
element B-abstraction
is O
located O
in O
the O
region B-abstraction
between O
bases O
109 O
and O
100 O
of O
the O
human B-physical_entity
glut4 O
promoter B-physical_entity
. O

transduction B-physical_entity
of O
the O
srebp O
1c O
dominant O
negative B-abstraction
form B-abstraction
to O
differentiated O
3t3 O
l1 O
adipocytes O
caused O
a O
reduction B-abstraction
in O
the O
mrna O
levels O
of O
glut4 O
, O
suggesting O
that O
srebp O
1c O
mediates O
the O
transcription B-abstraction
of O
glut4 O
. O

in O
vivo O
chromatin O
immunoprecipitation O
revealed O
that O
refeeding O
increased O
the O
binding B-physical_entity
of O
srebp O
1 O
to O
the O
putative O
sterol O
response B-physical_entity
element B-physical_entity
in O
the O
glut4 O
. O

furthermore O
, O
treating O
streptozotocin O
induced O
diabetic B-physical_entity
rats O
with O
insulin O
restored O
srebp O
1 O
binding B-abstraction
. O

in O
addition B-abstraction
, O
we O
have B-physical_entity
identified O
an O
sp1 O
binding B-abstraction
site B-physical_entity
adjacent O
to O
the O
functional O
sterol O
response B-abstraction
element B-abstraction
in O
the O
glut4 O
promoter B-physical_entity
. O

the O
sp1 O
site B-physical_entity
appears O
to O
play B-abstraction
an O
additive O
role B-abstraction
in O
srebp O
1c O
mediated O
glut4 O
gene O
upregulation O
. O

these O
results O
suggest O
that O
upregulation O
of O
glut4 O
gene O
transcription B-abstraction
might B-abstraction
be O
directly O
mediated O
by O
srebp O
1c O
in O
adipose O
tissue O
. O


background B-abstraction
autologous O
fat B-abstraction
grafting B-abstraction
is O
a O
prevalent O
technique B-abstraction
used O
for O
softtissue O
augmentation B-abstraction
; O
however O
, O
the O
poor O
survival B-physical_entity
rate B-abstraction
of O
the O
grafted O
tissue O
remains B-physical_entity
a O
drawback B-abstraction
of O
this O
method B-abstraction
. O

although O
adipose O
derived O
stem B-physical_entity
cells O
ascs O
are O
an O
attractive O
candidate B-physical_entity
for O
enhancing O
graft B-abstraction
retention B-abstraction
, O
the O
poor O
posttransplantation O
viability B-abstraction
of O
these O
cells O
limits O
their O
application B-abstraction
. O

here B-physical_entity
we O
investigated O
whether O
overexpression O
of O
the O
antiapoptotic O
protein O
heat B-physical_entity
shock B-physical_entity
protein O
70 O
hsp70 O
could O
enhance O
ascs' O
therapeutic O
potential O
for O
fat B-abstraction
transplant B-abstraction
survival B-abstraction
. O

methods O
recombinant B-physical_entity
adenoviral O
vectors O
were O
used O
to O
overexpress O
hsp70 O
in O
ascs O
isolated O
from O
a O
healthy O
woman B-physical_entity
. O

the O
hsp70 O
expression B-physical_entity
was O
assessed O
by O
quantitative O
real B-O
time I-O
polymerase O
chain B-physical_entity
reaction I-physical_entity
and O
western O
blot B-abstraction
analyses O
. O

the O
adipose O
tissue O
granules O
aspirated O
from O
anotherwomanweremixed O
with O
ascs O
expressing O
green B-abstraction
fluorescent B-physical_entity
protein O
gfp O
tagged O
hsp70 O
group O
a O
or O
gfp O
alone O
group O
b O
, O
untreated O
ascs O
group O
c O
, O
and O
phosphate O
buffered O
saline O
group O
d O
. O

fat B-abstraction
mixtures O
were O
then O
injected O
subcutaneously O
into O
the O
backs O
of O
nude B-physical_entity
mice O
, O
and O
graft B-abstraction
survival B-physical_entity
was O
compared O
after O
3 O
months O
. O

results O
adipose O
derived O
stem B-physical_entity
cells O
transduced O
with O
recombinant B-physical_entity
adenoviral O
vectors O
exhibited O
significantly O
increased O
hsp70 O
expression B-physical_entity
in O
vitro O
. O

meanwhile B-abstraction
, O
weight B-physical_entity
retention B-abstraction
analyses O
demonstrated O
that O
fat B-abstraction
grafts O
using B-abstraction
the O
group O
a O
cell B-physical_entity
population B-abstraction
exhibited O
significantly O
higher O
survival B-physical_entity
rates O
than O
the O
other O
treatment B-abstraction
groups O
in O
vivo O
. O

moreover O
, O
histological O
analyses O
revealed O
that O
fat B-abstraction
grafts O
containing O
gfp O
hsp70 O
expressing O
ascs O
yielded O
significantly O
lower B-physical_entity
levels O
of O
tissue O
fibrosis O
and O
fat B-abstraction
cysts O
vacuoles O
, O
higher O
capillary B-physical_entity
densities O
, O
and O
increased O
numbers B-abstraction
of O
viable O
adipocytes O
than O
the O
control B-abstraction
groups O
. O

conclusions O
our O
data O
indicate O
that O
hsp70 O
overexpression O
enhances O
the O
efficacy B-abstraction
of O
asc O
therapy B-abstraction
by O
improving O
the O
survival B-abstraction
and O
quality B-abstraction
of O
the O
transplanted O
fat B-abstraction
tissues O
. O


angiogenesis B-physical_entity
, O
a O
process B-physical_entity
induced O
by O
hypoxia O
in O
visceral O
white B-abstraction
adipose O
tissues O
vwat O
in O
the O
context O
of O
obesity B-abstraction
, O
mediates O
obesity B-abstraction
induced O
metabolic O
dysfunction O
and O
insulin O
resistance B-physical_entity
. O

chronic O
intermittent O
hypoxia O
ih O
and O
sustained O
hypoxia O
sh O
induce O
body B-abstraction
weight I-physical_entity
reductions O
and O
insulin O
resistance B-physical_entity
of O
different O
magnitudes O
, O
suggesting O
different O
hypoxia O
inducible O
factor B-abstraction
hif O
1 O
alpha B-abstraction
related O
activity B-physical_entity
. O

eight O
week B-abstraction
old B-abstraction
male B-physical_entity
c57bl O
6j O
mice O
n O
10 O
12 O
group O
were O
exposed O
to O
either O
ih O
, O
sh O
, O
or O
room B-physical_entity
air B-physical_entity
ra O
. O

vwat O
were O
analyzed O
for O
insulin O
sensitivity B-abstraction
phosphorylated O
pakt O
akt O
, O
hif O
1 O
alpha B-abstraction
transcription B-physical_entity
using B-abstraction
chromatin O
immunoprecipitation O
chip B-abstraction
sequencing O
, O
angiogenesis B-physical_entity
using B-abstraction
immunohistochemistry B-abstraction
, O
and O
gene O
expression B-physical_entity
of O
different O
fat B-abstraction
cell I-abstraction
markers O
and O
hif O
1 O
alpha B-abstraction
gene O
targets O
using B-abstraction
quantitative O
polymerase O
chain B-physical_entity
reaction I-physical_entity
or O
microarrays O
. O

body B-abstraction
and O
vwat O
weights O
were O
reduced O
in O
hypoxia O
sh O
ih O
ra O
; O
p O
sh O
ra O
; O
p O
0 O
. O

001 O
. O

ih O
induces O
preferential O
whitening B-abstraction
of O
vwat O
, O
as O
opposed O
to O
prominent O
browning B-abstraction
in O
sh O
. O

unlike O
sh O
, O
ih O
elicits O
early O
hif O
1 O
alpha B-abstraction
activity B-abstraction
that O
is O
unsustained O
over B-abstraction
time B-abstraction
and O
is O
accompanied O
by O
concurrent O
vascular O
rarefaction B-abstraction
, O
inflammation B-abstraction
, O
and O
insulin O
resistance B-physical_entity
. O

thus O
, O
the O
dichotomous O
changes O
in O
hif O
1 O
alpha B-abstraction
transcriptional O
activity B-physical_entity
and O
brown B-abstraction
beige B-abstraction
white B-physical_entity
fat B-abstraction
balance B-abstraction
in O
ih O
and O
sh O
should O
enable O
exploration B-abstraction
of O
mechanisms O
by O
which O
altered O
sympathetic O
outflow B-physical_entity
, O
such O
as O
that O
which O
occurs O
in O
apneic O
patients O
, O
results O
in O
whitening B-abstraction
, O
rather O
than O
the O
anticipated O
browning B-abstraction
of O
adipose O
tissues O
that O
occurs O
in O
sh O
. O


adipose O
tissue O
is O
a O
rich O
source B-physical_entity
of O
multipotent O
mesenchymal O
stem B-physical_entity
like B-abstraction
cells O
, O
located O
in O
the O
perivascular O
niche B-physical_entity
. O

based O
on O
their O
surface B-physical_entity
markers O
, O
these O
have B-physical_entity
been O
assigned O
to O
two O
main B-physical_entity
categories O
cd31 O
cd45 O
cd34 O
cd146 O
cells O
adventitial O
stromal O
stem B-abstraction
cells O
ascs O
and O
cd31 O
cd45 O
cd34 O
cd146 O
cells O
pericytes O
pcs O
. O

these O
populations O
display B-abstraction
heterogeneity B-abstraction
of O
unknown B-physical_entity
significance B-abstraction
. O

we O
hypothesized O
that O
aldehyde O
dehydrogenase O
aldh O
activity B-abstraction
, O
a O
functional O
marker B-physical_entity
of O
primitivity O
, O
could O
help B-physical_entity
to O
better B-abstraction
define O
asc O
and O
pc O
subclasses O
. O

to O
this O
end B-physical_entity
, O
the O
stromal O
vascular O
fraction O
from O
a O
human B-physical_entity
lipoaspirate O
was O
simultaneously O
stained O
with O
fluorescent B-physical_entity
antibodies O
to O
cd31 O
, O
cd45 O
, O
cd34 O
, O
and O
cd146 O
antigens O
and O
the O
aldh O
substrate B-physical_entity
aldefluor O
, O
then O
sorted O
by O
fluorescence O
activated O
cell B-physical_entity
sorting B-abstraction
. O

individual B-physical_entity
ascs O
n O
67 O
and O
pcs O
n O
73 O
selected O
from O
the O
extremities O
of O
the O
aldh O
staining B-abstraction
spectrum B-abstraction
were O
transcriptionally O
profiled O
by O
fluidigm O
single B-abstraction
cell B-physical_entity
quantitative O
polymerase O
chain B-physical_entity
reaction I-physical_entity
for O
a O
predefined O
set B-physical_entity
n O
429 O
of O
marker B-physical_entity
genes O
. O

to O
these O
single B-abstraction
cell B-physical_entity
data O
, O
we O
applied O
differential B-abstraction
expression B-abstraction
and O
principal B-physical_entity
component B-abstraction
and O
clustering O
analysis B-abstraction
, O
as O
well B-physical_entity
as O
an O
original B-physical_entity
gene O
coexpression O
network B-physical_entity
reconstruction B-abstraction
algorithm B-abstraction
. O

despite B-abstraction
the O
stochasticity B-abstraction
at O
the O
single B-abstraction
cell B-physical_entity
level B-abstraction
, O
covariation O
of O
gene O
expression B-physical_entity
analysis B-abstraction
yielded O
multiple B-abstraction
network B-physical_entity
connectivity B-abstraction
parameters O
suggesting O
that O
these O
perivascular O
progenitor B-physical_entity
cell B-physical_entity
subclasses O
possess O
the O
following B-abstraction
order B-abstraction
of O
maturity B-abstraction
a O
aldh O
br O
asc O
most O
primitive B-physical_entity
; O
b O
aldh O
dim O
asc O
; O
c O
aldh O
br O
pc O
; O
d O
aldh O
dim O
pc O
least O
primitive B-physical_entity
. O

this O
order B-abstraction
was O
independently O
supported O
by O
specific B-abstraction
combinations O
of O
class B-abstraction
specific B-abstraction
expressed O
genes O
and O
further O
confirmed O
by O
the O
analysis B-abstraction
of O
associated O
signaling O
pathways O
. O

in O
conclusion B-abstraction
, O
single B-abstraction
cell B-physical_entity
transcriptional O
analysis B-abstraction
of O
four B-physical_entity
populations O
isolated O
from O
fat B-abstraction
by O
surface B-physical_entity
markers O
and O
enzyme O
activity B-abstraction
suggests O
a O
developmental O
hierarchy O
among O
perivascular O
mesenchymal O
stem B-abstraction
cells O
supported O
by O
markers O
and O
coexpression O
networks O
. O

stem B-physical_entity
cells2017 O
; O
35 O
1273 O
. O


extensive O
research B-abstraction
has O
been O
performed O
to O
determine O
the O
effect B-abstraction
of O
freezing B-physical_entity
protocol B-abstraction
and O
cryopreservation O
agents O
on O
the O
viability B-abstraction
of O
adipose O
tissue O
derived O
stromal O
stem B-physical_entity
cells O
ascs O
as O
well B-physical_entity
as O
other O
cells O
. O

unfortunately O
, O
the O
conclusion B-abstraction
one B-abstraction
may B-physical_entity
draw B-physical_entity
after O
decades O
of O
research B-abstraction
utilizing O
fundamentally O
similar O
cryopreservation O
techniques O
is O
that O
a O
barrier B-physical_entity
exists O
, O
which O
precludes O
full B-abstraction
recovery B-abstraction
. O

we O
hypothesize O
that O
agents O
capable O
of O
inducing B-abstraction
a O
subset O
of O
heat B-abstraction
shock B-physical_entity
proteins O
hsps O
and O
chaperones O
will B-abstraction
reduce O
the O
intrinsic O
barriers O
to O
the O
post B-physical_entity
thaw B-abstraction
recovery B-physical_entity
of O
ascs O
. O

ascs O
were O
exposed O
to O
43 O
degrees O
c O
for O
1 O
h O
to O
upregulate O
hsps O
, O
and O
the O
temporal O
hsp O
expression B-abstraction
profile B-abstraction
postheat O
shock B-physical_entity
was O
determined O
by O
performing B-abstraction
quantitative O
polymerase O
chain B-physical_entity
reaction I-physical_entity
pcr O
and O
western O
blotting O
assays O
. O

the O
expression B-abstraction
levels O
of O
hsp70 O
and O
hsp32 O
were O
found O
to O
be O
maximum B-physical_entity
at O
3 O
h O
after O
the O
heat B-physical_entity
shock B-abstraction
, O
whereas O
hsp90 O
and O
hsp27 O
remain O
unchanged O
. O

the O
heat B-physical_entity
shocked O
ascs O
cryopreserved O
during O
maximal O
hsps O
expression B-physical_entity
exhibited O
increased O
post B-abstraction
thaw B-physical_entity
viability B-abstraction
than O
the O
nonheat O
shocked O
samples O
. O

histochemical O
staining B-abstraction
and O
quantitative O
reverse B-abstraction
transcription B-physical_entity
pcr O
indicated O
that O
the O
asc O
differentiation B-physical_entity
potential O
was O
retained O
. O

thus O
, O
suggesting O
that O
the O
upregulation O
of O
hsps O
before O
a O
freezing B-physical_entity
insult B-abstraction
is O
beneficial O
to O
ascs O
and O
a O
potential O
alternative B-abstraction
to O
the O
use B-physical_entity
of O
harmful O
cryoprotective O
agents O
. O


the O
long O
term B-physical_entity
effect B-abstraction
of O
feeding B-abstraction
the O
catecholamine O
analog B-abstraction
ractopamine O
rac O
; O
ractopamine O
hydrochloride O
, O
elanco O
animal B-physical_entity
health O
, O
indianapolis O
, O
in O
on O
the O
expression B-abstraction
of O
genes O
involved O
in O
energy B-abstraction
and O
lipid O
metabolism B-physical_entity
in O
subcutaneous O
adipose O
tissue O
was O
studied O
. O

large B-abstraction
white I-abstraction
pigs O
84 O
kg O
were O
fed O
corn B-physical_entity
and O
soybean B-physical_entity
meal O
based O
diets O
supplemented O
with O
0 O
, O
20 O
, O
or O
60 O
mg O
kg O
of O
rac O
for O
14 O
, O
28 O
, O
or O
42 O
d O
. O

expression B-physical_entity
mrna O
abundance B-abstraction
in O
adipose O
tissue O
of O
sterol O
regulatory O
binding B-abstraction
protein O
1 O
srebp O
1 O
, O
ppar O
alpha B-abstraction
, O
ppar O
gamma O
2 O
, O
fatty B-physical_entity
acid O
synthase O
fas O
, O
glucose O
transporter B-physical_entity
4 O
glut4 O
, O
and O
stearoyl O
coa O
desaturase O
was O
determined O
by O
northern O
blotting O
. O

feed O
intakes O
did O
not O
differ O
, O
and O
rac O
20 O
and O
60 O
mg O
kg O
improved O
bw O
gain B-abstraction
at O
d O
14 O
, O
28 O
, O
and O
42 O
p O
0 O
. O

05 O
and O
increased O
loin O
eye B-abstraction
area B-abstraction
measured O
on O
d O
42 O
only O
; O
p O
0 O
. O

05 O
. O

expression B-physical_entity
of O
srebp O
1 O
and O
ppar O
gamma O
2 O
declined O
p O
0 O
. O

05 O
with O
rac O
by O
d O
28 O
and O
42 O
, O
whereas O
expression B-abstraction
of O
ppar O
alpha B-abstraction
was O
increased O
p O
0 O
. O

05 O
on O
d O
14 O
, O
28 O
, O
and O
42 O
. O

after O
14 O
d O
, O
expression B-abstraction
of O
fas O
and O
glut4 O
was O
decreased O
p O
0 O
. O

05 O
with O
60 O
mg O
kg O
of O
rac O
, O
whereas O
both O
rac O
concentrations O
attenuated O
fas O
expression B-abstraction
on O
d O
28 O
and O
42 O
. O

overall B-physical_entity
, O
adipose O
tissue O
stearoyl O
coa O
desaturase O
expression B-physical_entity
was O
not O
affected O
by O
rac O
but O
showed O
somewhat O
less O
expression B-physical_entity
p O
0 O
. O

15 O
on O
d O
28 O
at O
60 O
mg O
kg O
of O
rac O
. O

although O
prolonged O
, O
chronic O
rac O
feeding B-physical_entity
most O
likely O
downregulates O
adipose O
tissue O
membrane B-physical_entity
beta O
adrenergic O
receptors O
, O
mrna O
abundances O
of O
anabolic O
lipid O
metabolism B-physical_entity
transcription B-physical_entity
factors O
, O
glucose O
transporters O
, O
and O
enzymes O
srebp O
1 O
, O
ppar O
gamma O
2 O
, O
fas O
, O
glut4 O
were O
still B-physical_entity
attenuated O
up O
to O
d O
42 O
. O

conversely O
, O
a O
transcription B-physical_entity
factor B-abstraction
related O
to O
oxidative O
metabolism B-physical_entity
expression B-abstraction
ppar O
alpha B-abstraction
was O
enhanced O
. O

we O
conclude O
that O
even B-abstraction
after O
42 O
d O
, O
rac O
still B-abstraction
decreased O
expression B-abstraction
of O
lipogenic O
genes O
in O
adipose O
tissue O
by O
yet O
undefined O
cyclic O
adenosine O
monophosphate O
directed O
mechanisms O
, O
but O
in O
contemporary B-physical_entity
lean O
pigs O
, O
this O
effect B-abstraction
is O
likely O
of O
limited B-physical_entity
practical O
significance B-abstraction
. O


conveyor B-physical_entity
systems O
allow O
quick O
and O
efficient O
transportation B-physical_entity
for O
a O
wide O
variety B-abstraction
of O
materials O
, O
which O
make B-abstraction
them O
very O
popular O
in O
the O
material B-physical_entity
handling B-abstraction
and O
packaging B-abstraction
industries O
. O

many O
kinds O
of O
conveying B-abstraction
systems O
are O
available O
and O
used O
according O
to O
the O
various O
needs O
of O
different O
industries O
. O

adjustable O
speed B-abstraction
drives O
are O
used O
for O
the O
operation B-abstraction
of O
the O
conveyors O
used O
in O
a O
number B-abstraction
of O
industries O
. O

we O
can B-physical_entity
use B-physical_entity
adjustable O
electric B-physical_entity
drives O
in O
a O
number B-abstraction
of O
industrial O
applications O
. O

a O
typical O
adjustable O
speed B-abstraction
drive B-physical_entity
consists O
of O
an O
induction B-abstraction
motor B-physical_entity
and O
a O
power B-physical_entity
electronic B-O
converter I-O
. O

in O
most O
cases O
, O
motor B-physical_entity
speed B-abstraction
is O
commanded O
so O
that O
the O
control B-abstraction
system I-physical_entity
requires O
an O
actual O
speed B-abstraction
signal B-abstraction
for O
closing B-abstraction
the O
speed B-abstraction
loop B-abstraction
. O

in O
industrial O
applications O
, O
speed B-abstraction
sensors O
, O
as O
well B-physical_entity
as O
sensorless O
solutions O
, O
are O
used O
. O

due B-abstraction
to O
the O
possibility B-abstraction
of O
current B-abstraction
speed B-abstraction
sensor B-physical_entity
noises O
and O
for O
maintenance B-abstraction
and O
economic O
aspects O
, O
the O
trend B-abstraction
is O
to O
substitute B-abstraction
speed B-abstraction
sensors O
by O
computational O
solutions O
. O

comprehensive B-abstraction
reviews O
of O
the O
sensorless O
drives O
show B-abstraction
that O
there B-physical_entity
are O
still B-abstraction
some O
persistent O
problems O
associated O
with O
the O
sensorless O
control B-abstraction
, O
that O
needs O
new O
solutions O
. O

in O
asds O
, O
the O
advanced O
control B-physical_entity
approach B-physical_entity
of O
im O
is O
the O
foc O
method B-abstraction
, O
used O
in O
modern B-physical_entity
industrial O
drives O
. O

the O
current B-abstraction
stator B-physical_entity
controller B-physical_entity
is O
the O
integral B-abstraction
part B-physical_entity
of O
various O
foc O
systems O
. O

in O
the O
classical O
foc O
solution B-abstraction
, O
pi O
or O
hysteresis O
controllers O
are O
generally O
used O
. O

however O
, O
pccs O
are O
reported O
to O
have B-physical_entity
better B-physical_entity
properties O
. O

system B-abstraction
sensitivity B-abstraction
to O
inaccuracy B-abstraction
and O
changes O
of O
motor B-physical_entity
equivalent B-abstraction
circuit B-abstraction
parameters O
are O
another O
problem B-abstraction
in O
electrical O
drives O
. O

almost O
all O
of O
the O
foc O
systems O
are O
very O
sensitive B-physical_entity
to O
such O
inaccuracies O
; O
therefore O
, O
some O
parameters O
should O
be O
estimated O
online O
, O
and O
a O
robust O
structure B-physical_entity
of O
the O
control B-physical_entity
is O
required O
. O

the O
real B-O
time I-O
implementation B-abstraction
of O
the O
system B-abstraction
is O
an O
important O
task B-abstraction
even B-abstraction
for O
electric B-physical_entity
drives O
or O
power B-abstraction
converters O
. O


four B-physical_entity
groupa O
streptococcal O
glycolipopeptide O
vaccine O
candidates O
with O
different O
lipidic O
adjuvanting O
moieties O
were O
prepared O
and O
characterized O
. O

the O
immunogenicity O
of O
the O
compounds O
was O
evaluated O
by O
macrophage B-physical_entity
and O
dendritic O
cell B-physical_entity
uptake B-physical_entity
studies O
and O
by O
in O
vivo O
quantification B-abstraction
of O
systemic O
igg O
antibody O
by O
elisa O
. O

three O
of O
the O
candidates O
showed O
significant O
induction B-abstraction
of O
the O
igg O
response B-physical_entity
. O


despite B-abstraction
the O
immense O
public O
health O
successes O
of O
immunization B-abstraction
over B-abstraction
the O
past B-abstraction
century B-abstraction
, O
effective O
vaccines O
are O
still B-physical_entity
lacking O
for O
globally O
important O
pathogens O
such O
as O
human B-physical_entity
immunodeficiency O
virus B-physical_entity
, O
malaria O
, O
and O
tuberculosis O
. O

exciting O
recent O
advances O
in O
immunology B-abstraction
and O
biotechnology B-abstraction
over B-abstraction
the O
past B-abstraction
few O
decades O
have B-physical_entity
facilitated O
a O
shift B-physical_entity
from O
empirical O
to O
rational O
vaccine O
design B-physical_entity
, O
opening B-physical_entity
possibilities O
for O
improved O
vaccines O
. O

some O
of O
the O
most O
important O
advancements O
include O
i O
the O
purification B-abstraction
of O
subunit O
antigens O
with O
high B-physical_entity
safety B-abstraction
profiles O
, O
ii O
the O
identification B-abstraction
of O
innate O
pattern B-abstraction
recognition B-abstraction
receptors O
prrs O
and O
cognate B-physical_entity
agonists O
responsible O
for O
inducing B-abstraction
immune B-physical_entity
responses O
, O
and O
iii O
developments O
in O
nano O
and O
microparticle O
fabrication B-abstraction
and O
characterization B-abstraction
techniques O
. O

advances O
in O
particle B-physical_entity
engineering B-physical_entity
now B-abstraction
allow O
highly O
tunable O
physicochemical O
properties O
of O
particle B-physical_entity
based O
vaccines O
, O
including O
composition B-abstraction
, O
size B-abstraction
, O
shape B-abstraction
, O
surface B-abstraction
characteristics O
, O
and O
degradability O
. O

enhanced O
collaborative O
efforts O
between O
researchers O
in O
immunology B-abstraction
and O
materials O
science B-abstraction
are O
expected O
to O
rise B-abstraction
to O
next O
generation B-abstraction
vaccines O
. O

this O
process B-abstraction
will B-abstraction
be O
significantly O
aided O
by O
a O
greater O
understanding B-abstraction
of O
the O
immunological O
principles O
guiding O
vaccine O
antigenicity O
, O
immunogenicity O
, O
and O
efficacy B-abstraction
. O

with O
specific B-abstraction
emphasis B-abstraction
on O
prr O
targeted O
adjuvants O
and O
particle B-physical_entity
physicochemical O
properties O
, O
this O
review B-abstraction
aims O
to O
provide O
an O
overview O
of O
the O
current B-abstraction
literature B-abstraction
to O
guide B-abstraction
and O
focus B-abstraction
rational O
particle B-physical_entity
based O
vaccine O
design B-abstraction
efforts O
. O


critical O
issues O
about O
scientific O
reproducibility O
have B-physical_entity
been O
raised O
about O
biomedical O
research B-abstraction
, O
including O
the O
reliability O
of O
data O
and O
analyses O
within O
a O
given B-abstraction
study B-abstraction
. O

the O
case B-physical_entity
example B-abstraction
in O
this O
article B-physical_entity
examined O
a O
reproducibility O
issue B-physical_entity
pertaining O
to O
the O
use B-physical_entity
of O
administrative O
data O
systems O
for O
evaluation B-abstraction
of O
child B-physical_entity
maltreatment B-abstraction
cm O
prevention B-abstraction
, O
making B-abstraction
use B-physical_entity
of O
a O
prevention B-abstraction
study B-abstraction
conducted O
over B-abstraction
a O
decade B-abstraction
ago O
that O
provided O
a O
unique O
opportunity O
. O

the O
place B-abstraction
randomization B-abstraction
study B-physical_entity
, O
which O
randomized O
counties O
to O
condition B-abstraction
, O
found O
that O
community B-physical_entity
wide O
implementation B-abstraction
of O
a O
parenting O
and O
family B-physical_entity
support B-physical_entity
intervention B-abstraction
produced O
positive B-physical_entity
impact B-abstraction
on O
county B-physical_entity
wide O
rates O
for O
substantiated O
cm O
cases O
and O
out B-abstraction
of O
home B-physical_entity
placements O
, O
documented O
through O
a O
state B-physical_entity
information B-abstraction
system I-abstraction
. O

the O
key B-physical_entity
consideration B-abstraction
is O
whether O
and O
to O
what O
extent B-abstraction
the O
administrative O
record B-abstraction
data O
re O
examined O
retroactively O
a O
decade B-abstraction
later O
for O
the O
original B-physical_entity
study's O
time B-abstraction
period I-abstraction
would O
yield B-physical_entity
comparable O
results O
to O
those O
based O
on O
data O
acquired O
at O
the O
time B-abstraction
of O
the O
study B-abstraction
. O

the O
results O
indicated O
that O
despite B-abstraction
small B-abstraction
changes O
over B-abstraction
time B-abstraction
, O
the O
same O
data O
patterns O
and O
statistical O
effects O
were O
reproducible O
for O
the O
two O
archival O
outcome B-abstraction
variables O
. O

for O
substantiated O
cm O
, O
the O
reproduced O
analyses O
reflected O
higher O
effect B-abstraction
sizes O
and O
a O
clear B-physical_entity
pattern B-physical_entity
of O
reduction B-physical_entity
as O
a O
function B-abstraction
of O
intervention B-abstraction
. O

for O
out B-abstraction
of O
home B-physical_entity
placements O
, O
effect B-abstraction
sizes O
were O
quite O
comparable O
to O
the O
original B-abstraction
ones O
, O
reflecting O
preventive B-physical_entity
impact B-abstraction
. O

overall B-physical_entity
, O
this O
case B-abstraction
study I-abstraction
illustrated O
the O
verifiability O
of O
data O
reproducibility O
in O
the O
context O
of O
a O
population B-abstraction
outcome B-abstraction
evaluation B-abstraction
, O
which O
underscores O
the O
importance B-abstraction
of O
reliable O
population B-abstraction
prevalence B-abstraction
measurement B-abstraction
as O
an O
essential O
part B-abstraction
of O
a O
comprehensive B-abstraction
public O
health O
strategy B-abstraction
aimed O
at O
the O
prevention B-abstraction
of O
cm O
. O

c O
2016 O
elsevier O
ltd O
. O

all O
rights O
reserved O
. O


aims O
ancient B-physical_entity
dna O
adna O
extracted O
from O
historical O
bones B-physical_entity
is O
damaged O
and O
fragmented O
into O
short B-abstraction
segments O
, O
present B-abstraction
in O
low B-physical_entity
quantity B-abstraction
, O
and O
usually O
copurified O
with O
microbial O
dna O
. O

a O
wide O
range B-abstraction
of O
dna O
quantification B-abstraction
methods O
are O
available O
. O

the O
aim B-abstraction
of O
this O
study B-abstraction
was O
to O
compare B-abstraction
the O
five B-physical_entity
most O
common B-physical_entity
dna O
quantification B-abstraction
methods O
for O
adna O
. O

materials O
and O
methods O
quantification B-abstraction
methods O
were O
tested O
on O
dna O
extracted O
from O
skeletal O
material B-physical_entity
originating O
from O
an O
early O
medieval O
burial B-abstraction
site I-abstraction
. O

the O
tested O
methods O
included O
ultraviolet O
uv O
absorbance B-abstraction
, O
real B-O
time I-O
quantitative O
polymerase O
chain B-physical_entity
reaction I-physical_entity
qpcr O
based O
on O
sybr O
r B-abstraction
green B-physical_entity
detection B-abstraction
, O
real B-O
time I-O
qpcr O
based O
on O
a O
forensic O
kit B-physical_entity
, O
quantification B-abstraction
via O
fluorescent B-physical_entity
dyes O
bonded O
to O
dna O
, O
and O
fragmentary O
analysis B-abstraction
. O

differences O
between O
groups O
were O
tested O
using B-abstraction
a O
paired O
t O
test B-physical_entity
. O

results O
methods O
that O
measure B-physical_entity
total B-abstraction
dna O
present B-abstraction
in O
the O
sample B-physical_entity
nanodrop O
tm O
uv O
spectrophotometer B-physical_entity
and O
qubit O
r B-abstraction
fluorometer O
showed O
the O
highest O
concentrations O
. O

methods O
based O
on O
real B-O
time I-O
qpcr O
underestimated O
the O
quantity B-abstraction
of O
adna O
. O

the O
most O
accurate O
method B-abstraction
of O
adna O
quantification B-abstraction
was O
fragmentary O
analysis B-abstraction
, O
which O
also O
allows O
dna O
quantification B-abstraction
of O
the O
desired O
length B-abstraction
and O
is O
not O
affected O
by O
pcr O
inhibitors O
. O

conclusions O
methods O
based O
on O
the O
quantification B-abstraction
of O
the O
total B-abstraction
amount B-abstraction
of O
dna O
in O
samples O
are O
unsuitable O
for O
ancient B-physical_entity
samples O
as O
they O
overestimate B-abstraction
the O
amount B-abstraction
of O
dna O
presumably O
due B-abstraction
to O
the O
presence B-physical_entity
of O
microbial O
dna O
. O

real B-O
time I-O
qpcr O
methods O
give B-abstraction
undervalued O
results O
due B-abstraction
to O
dna O
damage B-abstraction
and O
the O
presence B-abstraction
of O
pcr O
inhibitors O
. O

dna O
quantification B-abstraction
methods O
based O
on O
fragment B-physical_entity
analysis B-abstraction
show B-abstraction
not O
only O
the O
quantity B-abstraction
of O
dna O
but O
also O
fragment B-physical_entity
length B-abstraction
. O


considerable O
evidence B-abstraction
suggests O
that O
adolescent B-physical_entity
exposure B-physical_entity
to O
delta B-physical_entity
9 O
tetrahydrocanabinol O
thc O
, O
the O
psychoactive O
component B-abstraction
in O
marijuana B-physical_entity
, O
increases O
the O
risk B-abstraction
of O
developing O
schizophrenia O
related O
symptoms O
in O
early O
adulthood B-abstraction
. O

in O
the O
present B-abstraction
study B-abstraction
, O
we O
used O
a O
combination B-abstraction
of O
behavioral O
and O
molecular O
analyses O
with O
in O
vivo O
neuronal O
electrophysiology O
to O
compare B-abstraction
the O
long O
termeffects O
of O
adolescent B-physical_entity
versus O
adulthood B-abstraction
thc O
exposure B-abstraction
in O
rats O
. O

we O
report B-abstraction
that O
adolescent B-physical_entity
, O
but O
not O
adult B-physical_entity
, O
thc O
exposure B-abstraction
induces O
long O
term B-physical_entity
neuropsychiatric O
like B-abstraction
phenotypes O
similar O
to O
those O
observed O
in O
clinical O
populations O
. O

thus O
, O
adolescent B-physical_entity
thc O
exposure B-abstraction
induced O
behavioral O
abnormalities O
resembling O
positive B-physical_entity
and O
negative B-physical_entity
schizophrenia O
related O
endophenotypes O
and O
a O
state B-physical_entity
of O
neuronal O
hyperactivity O
in O
the O
mesocorticolimbic O
dopamine O
da O
pathway B-physical_entity
. O

furthermore O
, O
we O
observed O
profound O
alterations O
in O
several O
prefrontal O
cortical O
molecular O
pathways O
consistent O
with O
sub B-physical_entity
cortical O
daergic O
dysregulation O
. O

our O
findings O
demonstrate O
a O
profound O
dissociation B-physical_entity
in O
relative B-physical_entity
risk B-abstraction
profiles O
for O
adolescent B-physical_entity
versus O
adulthood B-abstraction
exposure B-abstraction
to O
thc O
in O
terms O
of O
neuronal O
, O
behavioral O
, O
and O
molecular O
markers O
resembling O
neuropsychiatric O
pathology B-abstraction
. O


